Charles Tomek
Overview
Explore the profile of Charles Tomek including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
45
Followers
0
Related Specialty
Related Specialty
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nussbaum J, Hussain A, Ma B, Min K, Chen Q, Tomek C, et al.
Pharmacol Res Perspect
. 2022 Feb;
10(1):e00924.
PMID: 35106949
Gefapixant (MK-7264) is a first-in-class, selective antagonist of the P2X3 purinergic receptor currently being investigated as a therapeutic agent for the treatment of refractory or unexplained chronic cough. In non-clinical...
2.
Ankrom W, Jackson Rudd D, Schaeffer A, Panebianco D, Friedman E, Tomek C, et al.
Antimicrob Agents Chemother
. 2021 Sep;
65(12):e0093521.
PMID: 34516246
MK-8507 is a novel HIV-1 nonnucleoside reverse transcriptase inhibitor in clinical development with potential for once-weekly oral administration for the treatment of HIV-1 infection. Two randomized, double-blind, placebo-controlled phase 1...
3.
Gillespie G, Jackson Rudd D, Zhang S, Schaeffer A, Tomek C, Larson P, et al.
J Clin Pharmacol
. 2021 Aug;
62(2):199-205.
PMID: 34435371
MK-8507 is an investigational HIV-1 nonnucleoside reverse transcriptase inhibitor being developed for the treatment of HIV-1 infection. MK-8507 contains 2 trifluoromethyl groups that may result in fluoride release through metabolism,...
4.
Gillespie G, Jackson Rudd D, Zhang S, Schaeffer A, Tomek C, Larson P, et al.
J Clin Pharmacol
. 2021 Aug;
62(2):190-198.
PMID: 34432899
Chronic overexposure to fluoride can have deleterious effects in the musculoskeletal system. Some fluorine-containing therapeutics, such as voriconazole, release fluoride through metabolism. Therefore, drug-related fluoride exposure should be assessed for...
5.
Matthews R, Jackson Rudd D, Fillgrove K, Zhang S, Tomek C, Stoch S, et al.
Clin Drug Investig
. 2021 Jun;
41(7):629-638.
PMID: 34151413
Background And Objectives: Islatravir (MK-8591) is a novel nucleoside analogue in development for the treatment and prevention of HIV-1 infection. Doravirine is a non-nucleoside reverse transcriptase inhibitor indicated for the...
6.
Assessment of Pharmacokinetic Interaction Between Letermovir and Fluconazole in Healthy Participants
Adedoyin A, Fancourt C, Menzel K, Zhao T, Tomek C, Panebianco D, et al.
Clin Pharmacol Drug Dev
. 2020 Jul;
10(2):198-206.
PMID: 32700459
Letermovir is a prophylactic agent for cytomegalovirus infection and disease in adult cytomegalovirus-seropositive recipients of allogeneic hematopoietic stem cell transplant. As the antifungal agent fluconazole is administered frequently in transplant...
7.
Bellon A, Wang J, Skerjanec A, Velinova M, Dickerson D, Sabet A, et al.
Br J Clin Pharmacol
. 2020 Feb;
86(6):1139-1149.
PMID: 32022282
Aims: Recombinant PEGylated human granulocyte colony-stimulating factor (pegfilgrastim) is indicated for the reduction of chemotherapy-induced neutropenia and prevention of febrile neutropenia. Biosimilar pegfilgrastim is expected to reduce the financial burden...
8.
Miyazaki S, Katsube T, Shen H, Tomek C, Narukawa Y
J Clin Pharmacol
. 2019 Feb;
59(7):958-967.
PMID: 30730562
The objectives of this study were to characterize the concentration-time profiles of total radioactivity equivalent and unchanged cefiderocol, the route(s) of elimination and mass balance, and safety of cefiderocol after...